Lantern Pharma Inc.
Records under this name other than the patents Lantern Pharma Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,829,539 | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Term ended Term ended Nov 1, 2025 · From the USPTO record | Term ended | Term ended Nov 1, 2025 | From the USPTO record |
| US 7,829,117 | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Term ended Term ended Oct 28, 2025 · From the USPTO record | Term ended | Term ended Oct 28, 2025 | From the USPTO record |
| US 7,829,541 | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Term ended Term ended Oct 28, 2025 · From the USPTO record | Term ended | Term ended Oct 28, 2025 | From the USPTO record |
| US 7,829,540 | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Term ended Term ended Oct 27, 2025 · From the USPTO record | Term ended | Term ended Oct 27, 2025 | From the USPTO record |
| US 7,829,538 | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents Term ended Term ended Oct 26, 2025 · From the USPTO record | Term ended | Term ended Oct 26, 2025 | From the USPTO record |
| US 7,053,240 | Process for synthesizing disulfides Term ended Term ended Dec 17, 2024 · From the USPTO record | Term ended | Term ended Dec 17, 2024 | From the USPTO record |
| US 7,235,589 | Method of treating patients undergoing kidney dialysis Term ended Term ended Dec 11, 2024 · From the USPTO record | Term ended | Term ended Dec 11, 2024 | From the USPTO record |
| US 7,282,602 | Medicinal disulfide salts Term ended Term ended Nov 25, 2024 · From the USPTO record | Term ended | Term ended Nov 25, 2024 | From the USPTO record |
| US 6,504,049 | Process for synthesizing pharmaceutically active disulfide salts Term ended Term ended Apr 30, 2022 · From the USPTO record | Term ended | Term ended Apr 30, 2022 | From the USPTO record |
| US 8,710,095 | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity Lapsed on the fee record Ended Apr 29, 2022 · From the USPTO record | Lapsed on the fee record | Ended Apr 29, 2022 | From the USPTO record |